Quarterly ResultMar 29, 2026, 09:00 PM
Amgen Reports 2025 Full Year Revenue Up 10% to $36.8 Billion, GAAP EPS Up 88% to $14.23
AI Summary
Amgen announced its fourth quarter and full year 2025 financial results, reporting a 10% increase in full-year revenue to $36.8 billion and an 88% increase in GAAP earnings per share to $14.23. The company highlighted strong performance across its product portfolio, with several products achieving record sales, but also noted a $1.2 billion impairment charge related to Otezla due to Medicare price setting under the Inflation Reduction Act.
Key Highlights
- Total revenues increased 10% to $36.8 billion for the full year 2025 compared to 2024.
- GAAP EPS increased 88% to $14.23 for the full year, driven by higher revenues and gains on equity investments.
- Non-GAAP EPS increased 10% to $21.84 for the full year.
- The company recorded a $1.2 billion impairment charge related to Otezla due to the Inflation Reduction Act.
Price Impact
More from AMGN